monepantel

PharmAust (ASX: PAA) chief executive officer Michael Thurn joins Small Caps to discuss the company's ongoing success with its investigation into its lead treatment candidate monepantel (MPL).

PharmAust is focused on repurposing MPL for the treatment of human neurodegenerative disorders such as motor neurone disease (MND) / amyotrophic lateral sclerosis (ALS).

New top-line Phase 1 MEND study results have found that PharmAust has taken a significant step towards helping people diagnosed with this rare and incurable disease.

Notably, new tests have found that MPL displays a superior safety, tolerability to the leading FDA approved drug Relyvrio.

Preliminary efficacy data also found a 58% reduction in the rate of disease progression for high dose Cohort 2 patients using the FDA primary efficacy endpoint.

The result has demonstrated the potential to provide meaningful clinical benefit to people living with MND/ALS.

PharmAust also recently created a “dream team” of scientists including internationally renowned experts in MND/ALS drug discovery and clinical development who will provide PharmAust with strategic guidance in the development of MPL

Articles:
https://smallcaps.com.au/pharmaust-monepantel-study-shows-slowdown-mnd-progression/
https://smallcaps.com.au/pharmaust-world-class-scientific-advisory-board-fight-against-neurodegenerative-diseases/
https://smallcaps.com.au/pharmaust-monepantel-study-mnd-als-treatment-fast-track-fda-meeting/
https://smallcaps.com.au/pharmaust-begins-extended-study-mnd-treatment-successful-trial/

For more information on PharmAust:
https://smallcaps.com.au/stocks/asx-paa/

See omnystudio.com/listener for privacy information.

PharmAust (ASX: PAA) chief executive officer Michael Thurn joins Small Caps to discuss his appointment to the company and recent trial developments.

The company recently released interim analysis of data from a Phase 1 clinical trial of its lead drug candidate monepantel (MPL) to treat motor neurone disease/amyotrophic lateral sclerosis (MND/ALS).

Results from an interim analysis of the trial indicated that neurofilament light chain (Nfl) protein concentrations in the plasma of participants in its Phase 1 clinical trial do not increase following MPL treatment – a positive sign.

PharmAust hopes that MPL could eventually receive orphan drug designation by the Therapeutics Goods Administration (TGA) and US Food and Drug Administration (FDA) for motor neurone disease, which affects over 350,000 people globally and kills more than 100,000 people yearly.

Article:
https://smallcaps.com.au/pharmaust-names-highly-experienced-biotech-specialist-chief-executive-officer/
https://smallcaps.com.au/pharmaust-interim-phase-1-data-mpl-inhibit-motor-neurone-disease/

For more information on PharmAust:
https://smallcaps.com.au/stocks/asx-paa/ 

See omnystudio.com/listener for privacy information.